Statute Details
- Title: Human Biomedical Research (Tissue Banking) Regulations 2019
- Act Code: HBRA2015-RG3
- Type: Subsidiary Legislation (sl)
- Authorising Act: Human Biomedical Research Act 2015 (Section 63)
- Commencement: 1 November 2019
- Latest Revised Edition (as provided): 2025 Revised Edition (2 June 2025)
- Status (as provided): Current version as at 27 Mar 2026
- Regulatory Focus: Governance requirements for tissue banks and tissue used for human tissue transplantation research
- Key Parts: Part 1 (Preliminary); Part 2 (Tissue Banks Generally); Part 3 (Tissue for Human Tissue Transplantation Research); Part 4 (Miscellaneous)
- Key Definitions (Section 2): “human tissue transplantation”, “non-identifiable”, “principal person in charge designated”, “recipient”, “untoward occurrence”, plus references to the Human Biomedical Research Act 2015
What Is This Legislation About?
The Human Biomedical Research (Tissue Banking) Regulations 2019 (“Tissue Banking Regulations”) are Singapore’s detailed regulatory rules governing how tissue banks operate in the context of human biomedical research. In practical terms, the Regulations translate the broad framework of the Human Biomedical Research Act 2015 (“HBRA”) into operational obligations for tissue banks—covering notification duties, governance, donor confidentiality, traceability, safety, and quality management.
The Regulations are designed to ensure that tissue collected, stored, processed, supplied, or exported for research purposes is handled in a way that protects donors, maintains tissue integrity, and supports accountability when adverse events occur. They also impose additional requirements when tissue is intended for “human tissue transplantation” research—i.e., tissue transplantation or grafting between individuals or within the same body.
Although the HBRA provides the overarching legal authority, the Tissue Banking Regulations focus on “how” tissue banking must be done. For practitioners, the key value of the Regulations is that they specify procedural and compliance steps—such as what must be notified, what records must be tracked, what safety policies must exist, and what systems must be implemented—so that tissue banks can demonstrate compliance to regulators and manage risk.
What Are the Key Provisions?
1. Definitions that drive compliance scope (Part 1, Section 2). The Regulations’ definitions are not merely interpretive; they determine when obligations apply and how they are triggered. For example, “human tissue transplantation” is defined broadly to include transplantation or grafting of tissue within the same body (same part to same part; one part to another part) and between individuals. This breadth matters because Part 3 imposes additional requirements for tissue used in transplantation research.
Similarly, “non-identifiable” is tied to the HBRA concept in section 27(3), meaning that whether tissue is identifiable or not affects how donor information must be protected and how consent and records are handled. The definition of “principal person in charge designated” points to a governance requirement under the HBRA: a tissue bank must designate an individual responsible for compliance. The definition of “recipient” includes researchers and research institutions receiving tissue from a tissue bank, which is important for understanding downstream obligations (including notifications and contamination management). Finally, “untoward occurrence” is defined in a detailed, risk-oriented way, capturing serious safety and quality events—such as death, life-threatening outcomes, hospitalisation, disability, communicable disease transmission, misidentification/mix-up, and congenital anomalies/birth defects.
2. Tissue banks generally: notification, governance, and compliance declarations (Part 2). Part 2 sets out the baseline compliance duties for tissue banks. While the extract provided lists the headings rather than the full text of each section, the structure is clear and practitioner-relevant. Tissue banks must comply with notification requirements (including notifications by the tissue bank and notifications under specified HBRA provisions), designate a “principal person in charge,” and keep information current (including change of information and particulars). The Regulations also require a “declaration of compliance” (First Schedule), which is a formal mechanism for a tissue bank to attest that it meets regulatory requirements.
Practically, these provisions are the backbone of regulatory oversight. Notification and declarations create an auditable trail for the regulator and help ensure that tissue banks operate transparently. The designation of a principal person in charge is particularly important for accountability: it ensures there is a named individual responsible for compliance management, escalation, and regulatory engagement.
3. Safety, traceability, and donor protection (Part 2). Part 2 also addresses operational safeguards. Key headings include:
- Requirements before tissue is removed, supplied or exported (Section 15): Tissue banks must not release tissue unless specified conditions are satisfied. This typically includes ensuring consent, safety checks, and appropriate documentation.
- Protection of confidentiality of donor’s information (Section 16): Donor privacy must be protected, with controls on access and disclosure.
- Tracking of consent and integrity of records (Section 17): The Regulations require traceability not only of the tissue but also of consent and the integrity of records—supporting both patient/donor protection and regulatory auditability.
- Safety and welfare of donors (Section 18): Donor welfare is a core compliance objective, requiring tissue banks to manage donor-related risks.
- Policy on incidental findings (Section 19): Where incidental findings arise, the tissue bank must have a policy addressing how such findings are handled (including communication and governance decisions).
For legal and compliance teams, these provisions collectively require a “compliance system,” not just ad hoc decision-making. A tissue bank should be able to demonstrate (i) what it did before tissue was released, (ii) how it protected donor information, (iii) how it maintained traceability and record integrity, and (iv) how it managed donor welfare and incidental findings.
4. Adverse event reporting: serious adverse events and untoward occurrences (Sections 10–13). The Regulations include multiple notification provisions relating to adverse events. The headings distinguish between:
- Notification of serious adverse event (Section 10) and notification by tissue bank of serious adverse event (Section 11),
- Notification of untoward occurrence arising from removal of tissue under HBRA section 35(3)(c) (Sections 12 and 13).
Even without the full text in the extract, the compliance implication is clear: tissue banks must have defined processes for identifying, classifying, documenting, and reporting adverse events and untoward occurrences. Because “untoward occurrence” is defined to include misidentification or mix-up, the reporting regime is also a quality management tool—designed to prevent recurrence and to ensure regulator awareness of systemic risks.
5. Additional requirements for tissue used in transplantation research (Part 3). Part 3 applies to “tissue for human tissue transplantation research” and imposes extra requirements beyond the general tissue bank obligations. The headings indicate a structured approach:
- Application of this Part (Section 20): clarifies when Part 3 applies.
- Documentation (Section 21): requires specific documentation for transplantation-related research.
- Tracking of information relevant to safety and quality (Section 22): strengthens traceability for transplantation contexts.
- Additional requirements before tissue is released, supplied or exported (Section 23): adds further release conditions.
- Notification by recipient of human tissue (Section 24): shifts some compliance duties downstream to recipients.
- Management of tissue contamination (Section 25): requires contamination controls and response measures.
- Quality and safety management systems (Section 26): mandates formal systems—typically including SOPs, training, audits, and corrective/preventive actions.
For practitioners advising tissue banks or research institutions, Part 3 is where the regulatory burden increases. It is also where contractual and operational alignment becomes critical: recipients must understand their notification duties and how contamination or safety issues must be escalated.
6. Miscellaneous compliance: electronic systems, false information, and fees (Part 4). Part 4 includes practical administrative provisions. “Electronic system” (Section 27) indicates that notifications or submissions may be made through an electronic platform. The definition of “relevant website” in Section 2 points to https://elis.moh.gov.sg/tiaras, suggesting the regulatory portal for tissue banking-related matters. “False information” (Section 28) signals enforcement risk for inaccurate or misleading submissions. “Fees” (Section 29) is supported by the Second Schedule, which is relevant for budgeting and compliance planning.
How Is This Legislation Structured?
The Regulations are organised into four Parts:
- Part 1 (Preliminary): Contains the citation and core definitions (including Section 2).
- Part 2 (Tissue Banks Generally): Establishes baseline obligations for tissue banks, including notifications, governance (principal person in charge), declarations of compliance, donor confidentiality, consent and record integrity tracking, donor welfare, incidental findings policy, and adverse event/untoward occurrence reporting.
- Part 3 (Tissue for Human Tissue Transplantation Research): Adds transplantation-specific requirements, including enhanced documentation and tracking, additional release/supply/export conditions, recipient notifications, contamination management, and quality and safety management systems.
- Part 4 (Miscellaneous): Covers electronic systems for regulatory interactions, offences/risks relating to false information, and fees (with a schedule).
- Schedules: The First Schedule contains the declaration of compliance form; the Second Schedule sets out fees.
Who Does This Legislation Apply To?
The Regulations apply primarily to tissue banks operating in Singapore in connection with human biomedical research. They also apply to recipients—including researchers and research institutions—that receive tissue directly or indirectly from a tissue bank, particularly where the tissue is used for human tissue transplantation research (Part 3).
In addition, the Regulations’ adverse event and untoward occurrence reporting provisions create compliance touchpoints for tissue banks and, in transplantation contexts, for recipients. Practitioners should therefore treat the Regulations as a shared compliance framework spanning both supply-side (tissue banks) and demand-side (research institutions) actors.
Why Is This Legislation Important?
The Tissue Banking Regulations are important because they operationalise patient/donor protection and research integrity in a high-risk area: the handling of human tissue for research, including tissue that may be transplanted or grafted. The detailed definition of “untoward occurrence” reflects a risk-based approach that includes not only clinical outcomes (death, life-threatening events, disability) but also quality failures (misidentification or mix-up) and public health risks (transmission of communicable disease).
From an enforcement and litigation-risk perspective, the Regulations’ emphasis on notification, traceability, record integrity, and quality management systems means that compliance failures can quickly become evidential issues. A tissue bank that cannot produce documentation of consent tracking, release conditions, or adverse event reporting may face regulatory action and reputational harm, and may also face civil or professional exposure depending on the facts.
For practitioners advising clients, the most practical takeaway is to ensure that compliance is embedded in operational workflows: governance structures (principal person in charge), documentation and audit trails, donor confidentiality controls, adverse event classification and reporting processes, and transplantation-specific quality systems. The existence of a declaration of compliance and fee schedules further indicates that regulators expect formal, repeatable compliance practices rather than informal assurances.
Related Legislation
- Human Biomedical Research Act 2015 (authorising Act; including provisions referenced in the Regulations such as section 35 and section 27(3))
Source Documents
This article provides an overview of the Human Biomedical Research (Tissue Banking) Regulations 2019 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.